Evidence map›Paper›PMID 41214414›Full record

ArticleDermatology and therapy2026

Real-World Evidence on Dose Spacing of Risankizumab for Psoriasis: A Multicenter Retrospective Cohort Study.

Martim Luz, Ana Luísa João, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite, Joana Valério, Ana Ferreirinha, Barbara Leal, Maria João Paiva Lopes, Rita Pimenta and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Journal of inflammation research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Martim LuzDepartment of Dermatology, Centro Académico Clínico ICBAS/Santo António, Porto, Portugal.
Ana Luísa JoãoDepartment of Dermatology, ULS de São José, Lisbon, Portugal.
Pedro Mendes-BastosDermatology Center, Hospital CUF Descobertas, Lisbon, Portugal.
Ângela RodaDermatology Center, Hospital CUF Descobertas, Lisbon, Portugal.
Luiz LeiteClínica Laser Belém, Lisbon, Portugal.
Joana ValérioClínica Laser Belém, Lisbon, Portugal.
Ana FerreirinhaDepartment of Dermatology, ULS de São José, Lisbon, Portugal.
Barbara LealInstituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
Maria João Paiva LopesDepartment of Dermatology, ULS de São José, Lisbon, Portugal.
Rita PimentaDermatology Center, Hospital CUF Descobertas, Lisbon, Portugal.
Paulo FerreiraDermatology Center, Hospital CUF Descobertas, Lisbon, Portugal.
Tiago TorresDepartment of Dermatology, Centro Académico Clínico ICBAS/Santo António, Porto, Portugal. torres.tiago@outlook.com.ORCID http://orcid.org/0000-0003-0404-0870

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dose spacingEffectivenessIL-23 inhibitorPsoriasisReal-world evidenceRisankizumab

Identifiers

PMID41214414
PMCPMC12873057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.